Tumor cell lysis and synergistically enhanced antibody-dependent cell-mediated cytotoxicity by NKG2D engagement with a bispecific immunoligand targeting the HER2 antigen.

ULBP2:HER2-scFv simultaneously bound to HER2 and NKG2D and triggered NK cells to kill HER2-expressing tumor cells in the nanomolar concentration range. Keywords: ADCC; antibody therapy; EGFR; NK cells; NKG2D EN ADCC antibody therapy EGFR NK cells NKG2D 545 556 12 04/12/22 20220401 NES 220401 Introduction Exploiting natural killer (NK) cells is a promising approach in cancer immunotherapy. ULBP2:HER2-scFv induces NK cell cytotoxicity To analyze whether ULBP2:HER2-scFv was able to trigger NK cell cytotoxicity SP 51 sp Cr release experiments were performed (Figure 3A). [Extracted from the article]